Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.008
Sell
RSI(14)
50.496
Neutral
STOCH(KDJ)(9,3,3)
67.713
Buy
ATR(14)
0.431
Low Volatility
CCI(14)
30.843
Neutral
Williams %R
50.307
Neutral
TRIX(12,20)
-0.401
Sell
StochRSI(14)
41.710
Sell
Search
Sellas Life Sciences Group Inc
SLS4.760USD
-0.290-5.74%
Close 04/10, 16:00（ET）Quotes delayed by 15 min
7.84KMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sellas Life Sciences Group Inc
Currency: USD Updated: 2026-04-09Key Insights
Sellas Life Sciences Group Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 390 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.67.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sellas Life Sciences Group Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sellas Life Sciences Group Inc Highlights
StrengthsRisks
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Undervalued
The company’s latest PE is -20.50, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.63M shares, decreasing 0.60% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 11.48K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.25.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.667
Target Price
+78.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-04-09The current financial score of Sellas Life Sciences Group Inc is 6.98, ranking 150 out of 390 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.36
Operational Efficiency
2.77
Growth Potential
6.75
Shareholder Returns
7.03
Sellas Life Sciences Group Inc's Company Valuation
Currency: USD Updated: 2026-04-09The current valuation score of Sellas Life Sciences Group Inc is 6.08, ranking 329 out of 390 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.50, which is -98.16% below the recent high of -0.38 and -8.51% above the recent low of -22.25.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 95/390
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-04-09The current earnings forecast score of Sellas Life Sciences Group Inc is 8.67, ranking 71 out of 390 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.50 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.667
Target Price
+92.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
550
Total
6
Median
6
Average
Company name
Ratings
Analysts
Sellas Life Sciences Group Inc
SLS
3
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
25
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-04-09The current price momentum score of Sellas Life Sciences Group Inc is 9.11, ranking 77 out of 390 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.84 and the support level at 4.10, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.742
Buy
MA10
4.465
Buy
MA20
4.803
Sell
MA50
4.592
Buy
MA100
3.702
Buy
MA200
2.757
Buy
Institutional Confidence
Currency: USD Updated: 2026-04-09The current institutional shareholding score of Sellas Life Sciences Group Inc is 3.00, ranking 198 out of 390 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 19.84%, representing a quarter-over-quarter decrease of 4.60%. The largest institutional shareholder is The Vanguard, holding a total of 8.47M shares, representing 4.71% of shares outstanding, with 50.94% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
State Street Investment Management (US)
Millennium Management LLC
Marshall Wace LLP
Two Sigma Investments, LP
Nuveen LLC
Northern Trust Investments, Inc.
Morgan Stanley Smith Barney LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-04-09The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sellas Life Sciences Group Inc is 3.21, ranking 160 out of 390 in the Biotechnology & Medical Research industry. The company's beta value is 2.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.34
VaR
+7.58%
240-Day Maximum Drawdown
+36.53%
240-Day Volatility
+99.99%
Return
Best Daily Return
60 days
+18.79%
120 days
+18.79%
5 years
+42.42%
Worst Daily Return
60 days
-11.82%
120 days
-18.00%
5 years
-54.10%
Sharpe Ratio
60 days
+2.06
120 days
+2.31
5 years
+0.30
Risk Assessment
Maximum Drawdown
240 days
+36.53%
3 years
+72.35%
5 years
+96.31%
Return-to-Drawdown Ratio
240 days
+7.58
3 years
+1.03
5 years
-0.13
Skewness
240 days
+0.29
3 years
+0.23
5 years
-0.91
Volatility
Realised Volatility
240 days
+99.99%
5 years
+112.93%
Standardised True Range
240 days
+4.81%
5 years
+4.72%
Downside Risk-Adjusted Return
120 days
+438.56%
240 days
+438.56%
Maximum Daily Upside Volatility
60 days
+69.04%
Maximum Daily Downside Volatility
60 days
+58.62%
Liquidity
Average Turnover Rate
60 days
+2.91%
120 days
+2.54%
5 years
--
Turnover Deviation
20 days
-24.64%
60 days
+9.47%
120 days
-4.67%
Peer Comparison
Biotechnology & Medical Research
Sellas Life Sciences Group Inc
SLS
6.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
